| Recruiting | Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma NCT05272384 | National Cancer Institute (NCI) | Phase 1 |
| Recruiting | Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatmen NCT04871607 | City of Hope Medical Center | Phase 2 |
| Withdrawn | Comparing ATG or Post-Transplant Cyclophosphamide to Calcineurin Inhibitor-Methotrexate as GVHD Prophylaxis Af NCT03602898 | Fred Hutchinson Cancer Center | Phase 2 |
| Active Not Recruiting | Low-Dose Selinexor and Choline Salicylate for Non-Hodgkin or Hodgkin Lymphoma, Histiocytic/Dendritic Cell Neop NCT04640779 | Mayo Clinic | Phase 1 |
| Completed | Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies NCT04681105 | City of Hope Medical Center | Phase 1 |
| Withdrawn | Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer NCT03739606 | City of Hope Medical Center | Phase 2 |
| Terminated | Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial NCT03878524 | OHSU Knight Cancer Institute | Phase 1 |
| Completed | Gemcitabine, Bendamustine, and Nivolumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma NCT03739619 | Emory University | Phase 1 / Phase 2 |
| Terminated | Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory No NCT03432741 | Mayo Clinic | Phase 1 |
| Recruiting | Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomo NCT03418038 | Mayo Clinic | Phase 2 |
| Completed | Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or NCT03213665 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients W NCT03096782 | M.D. Anderson Cancer Center | Phase 2 |
| Terminated | Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelate NCT03246906 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Brentuximab Vedotin, Cyclosporine, and Verapamil Hydrochloride in Treating Patients With Relapsed or Refractor NCT03013933 | City of Hope Medical Center | Phase 1 |
| Active Not Recruiting | Nivolumab, Ifosfamide, Carboplatin, and Etoposide as Second-Line Therapy in Treating Patients With Refractory NCT03016871 | City of Hope Medical Center | Phase 2 |
| Active Not Recruiting | Nivolumab & Brentuximab Vedotin Consolidation After Autologous SCT in Patients With High-Risk Classical Hodgki NCT03057795 | City of Hope Medical Center | Phase 2 |
| Completed | Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies NCT02960646 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant NCT02869633 | Vanderbilt-Ingram Cancer Center | Phase 2 |
| Active Not Recruiting | Busulfan, Fludarabine Phosphate, and Post-Transplant Cyclophosphamide in Treating Patients With Blood Cancer U NCT02861417 | M.D. Anderson Cancer Center | Phase 2 |
| Withdrawn | Gene-Modified HIV-Protected Stem Cell Transplant in Treating Patients With HIV-Associated Lymphoma NCT02378922 | Fred Hutchinson Cancer Center | Phase 1 |
| Completed | Ibrutinib and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma NCT02744612 | City of Hope Medical Center | Phase 2 |
| Completed | Ibrutinib in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma NCT02824029 | Barbara Ann Karmanos Cancer Institute | Phase 2 |
| Recruiting | Personalized NK Cell Therapy in CBT NCT02727803 | M.D. Anderson Cancer Center | Phase 2 |
| Terminated | Everolimus and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma NCT02254239 | Mayo Clinic | Phase 1 |
| Completed | Adoptive Immunotherapy in Relapsed Hematological Malignancy: Early GVHD Prophylaxis NCT02593123 | Virginia Commonwealth University | Phase 2 |
| Completed | Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or NCT02304458 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Brentuximab Vedotin, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory H NCT02227199 | University of Washington | Phase 1 / Phase 2 |
| Completed | Radiolabeled Monoclonal Antibody and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients NCT01921387 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |
| Completed | Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas NCT01897012 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Tran NCT01822509 | National Cancer Institute (NCI) | Phase 1 |
| Unknown | NK Cells in Cord Blood Transplantation NCT01619761 | M.D. Anderson Cancer Center | Phase 1 |
| Active Not Recruiting | Brentuximab Vedotin With or Without Nivolumab in Treating Patients With Relapsed or Refractory CD30+ Lymphoma NCT01703949 | University of Washington | Phase 2 |
| Completed | Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell NCT01527045 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Brentuximab Vedotin Before Autologous Stem Cell Transplant in Treating Patients With Hodgkin Lymphoma NCT01393717 | City of Hope Medical Center | Phase 2 |
| Completed | Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patient NCT01251575 | Fred Hutchinson Cancer Center | Phase 2 |
| Terminated | Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies NCT01028716 | Fred Hutchinson Cancer Center | Phase 2 |
| Terminated | Iodine I 131 Monoclonal Antibody BC8 Before Autologous Stem Cell Transplant in Treating Patients With Relapsed NCT00860171 | Fred Hutchinson Cancer Center | Phase 1 |
| Completed | Donor Lymphocyte Infusion in Treating Patients With Persistent, Relapsed, or Progressing Cancer After Donor He NCT00068718 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |